期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 52, 期 9, 页码 3441-3443出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00357-08
关键词
-
资金
- Cubist Pharmaceuticals (Lexington, MA)
- American Heart Association
- National Institute of General Medical Sciences [GM080602]
In a recent landmark trial of bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) isolates, vancomycin MICs were >= 1 mu g/ml for only 16% of the isolates, and accessory gene regulator (agr) function as measured by delta-hemolysin activity was absent or reduced in only 28.1% of the isolates. This clinical study did not capture a population of MRSA isolates predictive of vancomycin treatment failure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据